Synchron was founded in 2016 by Nicholas Opie and Thomas Oxley. Synchron has not officially endorsed or confirmed a plan to participate in an IPO.
Synchron is a bioelectric company that created neuromodulation technology for the medical treatment of brain and nervous system disorders. Per Forge data, Synchron has raised a total of $130 million in funding over 5 rounds, with their latest funding being raised on Dec 15, 2022, from a Series C round. Key investors include Khosla Ventures, Neurotechnology Investors, Sigma Partners, and ARCH Ventures.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Synchron is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Synchron pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Synchron is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.